Vimarsana
Biggest News Aggregation in the World

Page 26 - Olid News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Olid. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Olid Today - Breaking & Trending Today

Hera : Q1-23: Ongoing growth sustained by both organic growth and scope effects - Vimarsana News

Hera : Q1-23: Ongoing growth sustained by both organic growth and scope effects

SIGNIFICANT NEWSHera published a solid Q1 performance with strong organic growth in its two most strategic growing business units, energy and waste, amidst resilience for the gas segment. The Group... | May 11, 2023

PATRIZIA 3M 2023 financial results: Solid EBITDA growth driven by continued increase in management fees and lower net operating expenses - Vimarsana News

PATRIZIA 3M 2023 financial results: Solid EBITDA growth driven by continued increase in management fees and lower net operating expenses

EQS-News: PATRIZIA SE / Key word: Quarterly / Interim Statement/Quarter Results PATRIZIA 3M 2023 financial results: Solid EBITDA growth driven by continued increase in management fees and... | May 11, 2023

Rubicon and City of Atlanta Enter Smart City Partnership to Deliver Efficiency in Public Works Operations - Vimarsana News

Rubicon and City of Atlanta Enter Smart City Partnership to Deliver Efficiency in Public Works Operations

Rubicon’s smart city product is now powering the City of Atlanta’s entire solid waste, recycling, and street-sweeping fleet of 150 vehicles, digitizing operations and driving greater... | May 11, 2023

Yumanity Therapeutics : Dosed First Patient in Phase 1/2 Clinical Study of VISTA-Targeting KVA12123 in Advanced Solid Tumors Initial KVA12123 Clinical Data Readout Anticipated by End of 2023 Closed $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules - Form 8-K - Vimarsana News

Yumanity Therapeutics : Dosed First Patient in Phase 1/2 Clinical Study of VISTA-Targeting KVA12123 in Advanced Solid Tumors Initial KVA12123 Clinical Data Readout Anticipated by End of 2023 Closed $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules - Form 8-K

Dosed First Patient in Phase 1/2 Clinical Study of VISTA-Targeting KVA12123 in Advanced Solid Tumors Initial KVA12123 Clinical Data Readout Anticipated by End of 2023 ... | May 11, 2023

FRIWO AG: FRIWO with expected solid start in 2023 – E-mobility joint venture in India starts production at the end of May 2023 - Vimarsana News

FRIWO AG: FRIWO with expected solid start in 2023 – E-mobility joint venture in India starts production at the end of May 2023

EQS-News: FRIWO AG / Key word: Quarterly / Interim Statement/Quarter Results FRIWO AG: FRIWO with expected solid start in 2023 – E-mobility joint venture in India starts production... | May 10, 2023